This article is more than 5 years old. Information may no longer be current.

RegeneRx, U.S. military to test drug for treating eye damage from chemical agents

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

BETHESDA, Md. — RegeneRx has announced a collaboration with the U.S. Army Medical Research Institute of Chemical Defense and Gabriel Sosne, MD, associate professor of ophthalmology at Wayne State University, to evaluate the ability of its eye drop formulation of Tß4 for preventing or reducing damage to the eye caused by exposure to chemical agents, according to a press release from the company.

Over the next year, the partnership plans to conduct a series of research experiments with the drug, called, RGN-259.

"We are pleased to be working with U.S. military on this important project," J.J. Finkelstein, president and chief executive officer of RegeneRx, said in the release. "We hope their work will lead to the use of our technology for treatment of eyes exposed to caustic chemicals. RegeneRx is prepared to assist in any way possible to support efforts to protect our military personnel and citizens from exposure to debilitating or life-threatening chemical agents."

Dr. Sosne and colleagues have published articles about the ability of Tß4 to reduce chemical agent damage by reducing inflammation and promoting cornea re-epithelialization.

RGN-259 is currently undergoing phase 2 clinical testing, the release said.